Skip to main content
GANX logo

Gain Therapeutics, Inc.

GANXNASDAQHealthcareBiotechnology

$1.17Today:- (-)1Y −34.52%

As of Oct 27, 2026 close

Market cap
$50.17M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$1.17$4.34
Volume (live)
-
Avg. volume (3M)
596.74K

Gain Therapeutics (GANX) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Gain Therapeutics reported total assets of $22.82M and total liabilities of $4.25M. Shareholders' equity was $18.56M, up 152.9% from $7.34M a year earlier. Total debt stood at $732.07K against $20.84M in cash and short-term investments, a net cash position of $20.11M. That puts debt-to-equity at 0.04, compared with 0.06 a year earlier.

Gain Therapeutics Balance Sheet Analysis

Values in millions USD

Scroll to see more
Balance sheet showing assets, liabilities, and shareholders' equity for Gain Therapeutics, Inc. (GANX) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Current Assets
Cash and Cash Equivalents20.8410.3911.797.3136.887.490.300.40
Short-Term Investments0.000.005.0012.830.000.000.000.00
Cash & Short-Term Investments20.8410.3916.7920.1436.887.490.300.40
Accounts Receivable0.800.770.240.190.200.070.040.00
Inventory0.000.000.000.000.000.000.000.00
Other Current Assets0.601.220.740.850.840.200.050.09
Total Current Assets22.2411.6017.7821.0937.728.990.400.49
Non-Current Assets
Property, Plant & Equipment (Net)0.410.320.590.801.010.550.220.31
Long-Term Investments0.040.030.031.940.030.000.010.00
Intangible Assets0.100.130.190.210.200.000.000.00
Other Non-Current Assets0.030.060.020.050.050.060.030.01
Total Non-Current Assets0.580.520.833.011.260.620.260.32
Total Assets22.8212.1218.6124.1038.999.600.660.81
Current Liabilities
Accounts Payable0.830.951.321.630.560.960.150.15
Short-Term Debt0.220.110.350.110.100.020.100.10
Current Portion of Long-Term Debt0.100.110.120.110.100.02--
Accrued Liabilities2.102.191.741.741.150.76--
Deferred Revenue0.000.251.120.060.270.240.370.00
Other Current Liabilities2.312.442.112.001.400.010.250.28
Total Current Liabilities3.353.914.954.132.552.110.880.53
Non-Current Liabilities
Long-Term Debt0.510.330.680.500.590.720.101.21
Other Non-Current Liabilities0.390.490.310.160.330.170.130.02
Total Non-Current Liabilities0.900.871.081.091.611.290.231.23
Total Liabilities4.254.786.035.224.173.401.111.76
Stockholders' Equity
Common Stock0.000.000.000.000.000.000.000.00
Retained Earnings-101.36-81.19-60.78-38.52-20.93-7.03-3.46-1.26
Accumulated Other Comprehensive Income0.78-0.250.250.04-0.09-0.15-0.080.00
Additional Paid-in Capital119.1488.7873.1157.3655.8313.393.090.31
Shares Outstanding42.0727.1316.2111.8811.88---
Total Stockholders' Equity18.567.3412.5818.8834.826.20-0.45-0.95
Total Liabilities & Equity22.8212.1218.6124.1038.999.600.660.81

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Gain Therapeutics Balance Sheet

How much debt does Gain Therapeutics have?

Gain Therapeutics had total debt of $732.07K as of Dec 31, 2025, against $20.84M in cash and short-term investments. Its debt-to-equity ratio was 0.04. Total debt was $438.50K a year earlier.

What are Gain Therapeutics's total assets?

Gain Therapeutics reported total assets of $22.82M as of Dec 31, 2025, up 88.2% from $12.12M a year earlier. Total liabilities were $4.25M.

What is Gain Therapeutics's shareholders' equity?

Gain Therapeutics's shareholders' equity was $18.56M as of Dec 31, 2025, or about $0.44 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition